Briacell Therapeutics Corp Stock Today
| BCTXW Stock | USD 0.34 0.03 9.68% |
Performance3 of 100
| Odds Of DistressOver 81
|
BriaCell Therapeutics is selling for under 0.34 as of the 26th of November 2024; that is 9.68% increase since the beginning of the trading day. The stock's lowest day price was 0.29. BriaCell Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for BriaCell Therapeutics Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of February 2021 | Category Healthcare | Classification Health Care |
BriaCell Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. More on BriaCell Therapeutics Corp
Moving together with BriaCell Stock
Moving against BriaCell Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BriaCell Stock Highlights
| President CEO | William MD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
BriaCell Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BriaCell Therapeutics' financial leverage. It provides some insight into what part of BriaCell Therapeutics' total assets is financed by creditors.
| |||||
BriaCell Therapeutics Corp (BCTXW) is traded on NASDAQ Exchange in USA. It is located in Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 and employs 6 people. BriaCell Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.08 M. BriaCell Therapeutics classifies itself under Biotechnology sector and is part of Health Care industry.
BriaCell Therapeutics generates negative cash flow from operations
Check BriaCell Therapeutics Probability Of Bankruptcy
BriaCell Therapeutics Historical Income Statement
BriaCell Stock Against Markets
BriaCell Therapeutics Corporate Management
| FACP MD | Founder Director | Profile | |
| Miguel LopezLago | Chief Officer | Profile | |
| Farrah Dean | Mang Devel | Profile | |
| MD MPH | Chief Officer | Profile |
Additional Tools for BriaCell Stock Analysis
When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.